Powered by
ANN ARBOR—Officials at Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR), a pharmaceutical startup developing a new class of cholesterol-lowering drugs, announced a $200 million funding agreement with an investor group …
ROCHESTER—Officials of OptimizeRx Corp. (Nasdaq: OPRX), the provider of digital marketing messaging for the pharmaceutical industry, said the company is expected to join the Russell Microcap and Russell 3000 stock …
(Updated June 5 with stock price) ROCHESTER—OptimizeRx Corp. (Nasdaq: OPRX), the Rochester-based provider of digital communication services for pharmaceutical companies to patients and healthcare providers, has announced a proposed underwritten …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging for the pharmaceutical industry, reported net income of $6,529 in the first quarter ended March 31, vs. a loss of …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) has provided a development update for its lead drug candidate, bempedoic acid, and financial results for the first quarter ended March 31. “The potential of …
ANN ARBOR—An Ann Arbor company that has developed a system to screen cancer patients to precision-designed treatments that will be most effective for them has a new clinical development collaboration …
ROCHESTER—Officials at OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging in the pharmaceutical industry, announced the appointment of Stephen Silvestro to the new position of chief commercial officer. …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), the digital health messaging provider for the pharmaceutical industry, announced its latest platform integration with the health care industry’s leading acute electronic health record (EHR) systems, …
SAGINAW—Graminex L.L.C. announced it had received Health Canada approval for its PollenBerry Flower Pollen Extract. The approval came under Health Canada’s Natural and Non-prescription Health Products Directorate. PollenBerry is a …
ANN ARBOR – Esperion Therapeutics Inc. (NASDAQ:ESPR), the pharmaceutical startup developing a new cholesterol-fighting drug, reported a loss of $60 million in the fourth quarter, up from a loss of $37.9 …